Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3839-3844

  Cai, Fengfeng ^a,b   Ge, Isabell ^c   Wang, Minghong ^a   Biskup, Ewelina ^d   Lin, Xiaoyan ^a   Zhong, Xiaoyan ^b  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

BRCA1; Breast cancer; Methylation; Pyrosequencing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CPG ISLAND; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; METHYLATION; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, BRCA1; HUMANS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; SEQUENCE ANALYSIS, DNA;

EID: 84898819164     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1508-2     Document Type: Article

References (27)

1. Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ, Zhong XY. Epigenetic therapy for breast cancer. Int J Mol Sci. 2011;12:4465-87.
2. Lin X, Cai F, Li X, et al. Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer. Tumour Biol. 2013;34:3239-43.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
4. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-21.
5. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-6.
6. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. 2003;348:2339-47.
7. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
8. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120-2.
9. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564-9.
10. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-7.
11. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-34.
12. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293-301.
13. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature. 1980;283:593-6.
14. Martin-Oliva D, Aguilar-Quesada R, O'valle F, et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006;66:5744-56.
15. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92.
16. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003;3:253-66.
17. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2:2265-75.
18. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-5.
19. Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol. 2011;780:277-91.
20. Veeck J, Ropero S, Setien F, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010;28:563-4.
21. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 1998;58:3237-42.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
23. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9.
24. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-59.
25. Tuma RS. PARP inhibitors: will the new class of drugs match the hype? J Natl Cancer Inst. 2009;101:1230-2.
26. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008;124:31-42.
27. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539-48.